Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation

NCT03050892 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-02-13

No results posted yet for this study

Summary

Evaluate the association between donor soluble protein ST2 (sST2) serum levels and 30-day recipient mortality in order to improve graft screening.

Conditions

  • Heart Transplant Failure and Rejection

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-03-01
Completion
2018-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03050892 on ClinicalTrials.gov